v3.26.1
Segment Reporting - Summary of Operating Financial Results (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total revenue $ 0 $ 0
Significant segment expenses:    
Research and development expense 312 808
Loss on disposal of assets 37 26
Gain on lease termination 0 (5,974)
Total operating expenses 1,640 (2,923)
Gain on settlement of accounts payables 0 191
Change in fair value of contingent liability (188) (136)
Total other (expense) income, net (188) 87
Net income (1,828) 3,010
Biotechnology Segment    
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]    
Total revenue 0 0
Significant segment expenses:    
Research and development expense 312 808
General and administrative expense 1,291 2,217
Loss on disposal of assets 37 26
Gain on lease termination 0 (5,974)
Total operating expenses 1,640 (2,923)
Interest and dividend income 0 32
Gain on settlement of accounts payables 0 191
Change in fair value of contingent liability (188) (136)
Total other (expense) income, net (188) 87
Net income $ (1,828) $ 3,010